NEOLISE Launches CJC-1295 and Ipamorelin Protocol for Longevity Support
News related to:NEOLISE · 2 min read
NEOLISE, a provider of compounded peptide protocols, has released a detailed review of its CJC-1295 and ipamorelin protocol, designed to support the body's natural growth hormone production. This review, conducted in September 2026, examines the current pricing, prescription process, and FDA status of the NEOLISE Longevity program.
The NEOLISE Longevity protocol combines CJC-1295, a growth hormone releasing hormone analog, and ipamorelin, a selective growth hormone secretagogue. These two peptides are compounded by an independent U.S. pharmacy and shipped to customers after approval by an independent licensed medical provider. NEOLISE’s subscription-based program offers plans ranging from $239 to $299 per month, depending on the term length. The program is geared toward individuals already committed to their health and wellness routines, particularly those focused on sleep, recovery, and body composition.
According to the NEOLISE website, the protocol is designed to complement existing health practices rather than replace them. The brand positions the program as a non-synthetic approach, offering a more natural method of growth hormone support compared to synthetic human growth hormone (HGH) injections. The program is intended for individuals who are already tracking their sleep, recovery, and body composition, and are seeking a provider-guided approach to longevity.
The NEOLISE Longevity protocol includes two key components: 1. CJC-1295 (1.2mg/mL), This compound is described as a growth hormone releasing hormone analog that signals the pituitary gland to sustain elevated growth hormone production over a period of days. 2. Ipamorelin (2mg/mL), This is a selective growth hormone secretagogue that activates the ghrelin receptor to trigger release of stored growth hormone in pulses. NEOLISE emphasizes the selectivity of ipamorelin, distinguishing it from older-generation growth hormone secretagogues, particularly in terms of its effects on cortisol, prolactin, and ACTH.
However, NEOLISE's program is not without regulatory concerns. The FDA has identified potential significant safety risks associated with CJC-1295 in compounding contexts. The FDA’s Pharmacy Compounding Advisory Committee has voted against including CJC-1295-related and ipamorelin-related bulk substances on the Section 503A Bulks List, citing concerns over limited clinical safety data, potential impurities, and reported adverse effects. This regulatory history is important for consumers to consider before engaging with the program.
In terms of how the protocol works, NEOLISE provides detailed instructions for administration. The CJC-1295/Ipamorelin vial is pre-mixed and shipped refrigerated between 36°F and 46°F. The vial must be administered subcutaneously, with dosing and schedules set by the prescriber. Each shipment includes insulin syringes, alcohol prep pads, and written instructions. NEOLISE ships in three-month batches, with check-ins included in the monthly plan price for 6- and 12-month subscriptions.
The NEOLISE program is not marketed as a replacement for lifestyle basics such as sleep, training, and nutrition. The company emphasizes that the protocol is intended for individuals who are already serious about their health and wellness routines. NEOLISE frames its audience around several recognizable types: the age-defier, the non-synthetic option seeker, the researcher, and the long-game player.
In conclusion, the NEOLISE Longevity program offers a compounded peptide protocol for individuals seeking to support their natural growth hormone production. While the program has its benefits, potential consumers should be aware of the regulatory concerns and the importance of working with a licensed medical provider.